Observational Study on the Use of Ivermectin as an Outpatient Treatment Option for COVID-19
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05045937|
Recruitment Status : Not yet recruiting
First Posted : September 16, 2021
Last Update Posted : September 17, 2021
|Condition or disease||Intervention/treatment|
|Covid19 COVID-19 Pneumonia COVID-19 Respiratory Infection COVID-19 Acute Bronchitis||Drug: Ivermectin|
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||1000 participants|
|Target Follow-Up Duration:||4 Weeks|
|Official Title:||Ivermectin Will be Used as an Outpatient Treatment Option for COVID-19 Patients.|
|Estimated Study Start Date :||September 20, 2021|
|Estimated Primary Completion Date :||September 20, 2023|
|Estimated Study Completion Date :||September 20, 2023|
COVID-19 patients treated with Ivermectin
This group of patients will be those who requested to be treated with Ivermectin and whom have been prescribed such by different physicians. This group may or may not include those treated with Monoclonal Antibodies or Remdesivir.
Ivermectin treatment of outpatients dosing at 0.4mg/kg until recovered along with supplemental treatment using a multi-modal approach.
COVID-19 patients declining Ivermectin and wanting traditional treatment
This group of patients will be those who do not request to be treated with Ivermerctin and who want to be treated with a more traditional, minimalist approach. This group may or may not include those treated with Monoclonal Antibodies or Remdesivir.
- Complete recovery from COVID-19 with resolution of symptoms [ Time Frame: 4-6 weeks per individual ]This group recovered completely from COVID-19 and remained an outpatient throughout the duration of their illness.
- Admission to a hospital for further advanced treatment [ Time Frame: 4-6 weeks per individual ]This group of patients was unable to recover at home and required hospital admission
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05045937
|Contact: Patrick R Robinson, MDfirstname.lastname@example.org|
|Contact: Dana M Robinson, RNemail@example.com|
|Principal Investigator:||Patrick r Robinson, MD||Patrick Robinson MD LLC|